Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IFM 2018-04 intensive quadruplet therapy with tandem autologous stem cell transplantation for newly diagnosed high-risk multiple myeloma
2018-001960-45Phase 2Active
- Sponsor
- CHU de Nantes
- Start
- Jan 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of carfilzomib, daratumumab, lenalidomide and dexamethasone in multiple myeloma (MM), sponsored by CHU de Nantes. Primary endpoint: Percentage of patients receiving the second autologous stem cell transplant. Started Jan 2019; status: active.
02
Drugs
carfilzomibdaratumumablenalidomidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2018-001960-45.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001960-45.